Introducing Atlas®: Multi-organ Phenotyping in Non-alcoholic Steatohepatitis (NASH)
Date: 13 November 2020
Time: 4:30pm GMT | 11:30am ET
Atlas® is a metabolic imaging suite redefining multi-organ assessment for clinical trials in diabetes and metabolic disease. It provides quantitative metrics of health and function across multiple organs from a single 30-minute, non-contrast MR scan. The utility of Atlas will be presented in a series of webinars throughout TLMdX 2020.
- Current issues in liver disease trials
- How Body Comp metrics are being used to solve some of these
- The future of using multi-organ imaging in liver trials
Dr Marc Goldfinger
Product Specialist, Perspectum
Dr. Goldfinger has worked in the field of diagnostic pathology for over 9 years, in both neuroscience and gastrointestinal disease. Dr. Goldfinger has recently focused on integrating artificial intelligence into MR applications and digitized histopathology to better understand hepatobiliary disease and bowel disease in order to identify novel biomarkers that may better stratify and monitor bowel disorders.
Professor Carlos Duncker
Medical Science Liaison at Perspectum
Carlos started his career as an MD and completed residency programs in Internal Medicine and Nuclear Medicine as well as a PhD in Medicine and Surgery. Carlos was previously the head of the Nuclear Medicine and Molecular Imaging Department at the Children’s Hospital of Mexico, was Medical Advisor to the National Commission of Nuclear Safety and Safeguards and was Professor of Medical Physics at Autonomous National University of Mexico for several years. He has published 176 medical papers and was a Reviewer for the European Journal of Nuclear Medicine and Molecular Imaging under two Editors for more than a decade. He is a Distinguished Fellow of the American College of Nuclear Medicine and a Senior Member of the Mexican Academy of Surgery. Before joining Perspectum, Carlos managed the hepatology research at the Texas Digestive Disease Consultants (TDDC, the largest GI medical private practice in the USA). During his time at TDDC, Carlos positioned the hepatology research site as a top enroller for NASH clinical trials with the lowest screen failure rate among all US sites for multiple trials.
Dr Vidhya Kumar
Co-Lead, Pharma Solutions